MCV-related MCC therapies focus on restoring tumor suppressors (e.g., p53, pRB), targeting transcription factors (ATOH1, SOX2), and modulating pathways like NF-κB and YAP/TEAD. This evidence concerns the gene TP53 and Merkel cell skin cancer.